

NutraCoin White Paper



US\$25,000,000,000.00

25,000,000,000 Twenty-five Billion Tokens (“Tokens”)



Golden Sunrise Nutraceutical, Inc. (“Golden Sunrise”), a Delaware Corporation, is offering twenty-five billion (25,000,000,000) tokens of NutraCoin for US\$1.00 per Token.

*The offering price per token has been arbitrarily determined by the Company
-See Risk Factor: Offering Price.*

THESE ARE SPECULATIVE SECURITIES WHICH INVOLVE A HIGH DEGREE OF RISK. ONLY THOSE ACCREDITED INVESTORS WHO CAN BEAR THE LOSS OF THEIR ENTIRE INVESTMENT SHOULD INVEST IN THESE TOKENS.

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF YEAR-1933, AS AMENDED (THE “ACT”), THE SECURITIES LAWS OF THE STATE OF DELAWARE, OR UNDER THE SECURITIES LAWS OF ANY OTHER STATE OR JURISDICTION IN RELIANCE UPON THE EXEMPTIONS FROM REGISTRATION PROVIDED BY THE ACT AND REGULATION D RULE 506 PROMULGATED THEREUNDER, AND THE COMPARABLE EXEMPTIONS FROM REGISTRATION PROVIDED BY OTHER APPLICABLE SECURITIES LAWS.

Golden Sunrise Nutraceutical, Inc.

P.O. Box 510

PORTERVILLE, CA 93258

Phone No.: 1.559.781.0658

Fax No.: 1.559.615.1268

htieu@goldensunrisenutraceutical.com

www.goldensunrisenutraceutical.com

www.nutracoins.ai

The Date of this NutraCoin White Paper is January 01, 2026

TABLE OF CONTENTS

Title Page.....	1
Table of Contents.....	2
Definitions.....	3
Executive Summary.....	4
Introduction.....	6
Tokenization.....	10
Advisors.....	11
Company Overview.....	12
Requirements for Purchasers.....	13
Problem Statement.....	16
Target Market.....	16
Market Trends and Comparative Analysis.....	17
Risks and Mitigation.....	17
Legal and Compliance.....	18
Financial Forecasts and Income.....	18
Overview of Valuation.....	18
Risk Factors.....	21
Project Funding.....	24
Licensing.....	25
Conclusion.....	28
Frequently Asked Questions.....	28
Subscription Agreement.....	31

DEFINITIONS

Expression

Act
AML
App
ATS
CAGR
CIK
Company
DOJ
DUNS
EIN
Eqvista
Exchange Act
FDA
FAM
FD&C Act
FTC
GDPR
Golden Sunrise
GMP
IHA
IT
IRA
IRS
KYC
Medicare
Mrs. Fontana
Mr. Loeffler
Mr. Tieu
M&A
NDA
ORA
Purchaser
RBHL
R&D
RWA
SBIC
SEC
SC
STO
TCM
Tokens
UE
UI
U.S.
White Paper

Definition

Securities Act of Year-1933
Anti-Money Laundering
Application
Alternative Trading System
Compound Annual Growth Rate
Central Index Key
Golden Sunrise Nutraceutical, Inc.
U.S. Department of Justice
Dun & Bradstreet
Employer Identification Number
Eqvista, Inc.
Securities and Exchange
U.S. Food and Drug Administration
Financial Asset Management
Food, Drug, and Cosmetic Act
U.S. Federal Trade Commission
General Data Projection Regulation
Golden Sunrise Nutraceutical & Golden Sunrise Pharmaceutical
Good Manufacturing Practice
Investment Holding Account
Information Technology
Individual Retirement Account
Internal Revenue Code
Know Your Customer
Center for Medicare & Medicaid Services
Sonja I. FONTANA
Martin F. LOEFFLER
Huu S. TIEU
Merger and Acquisition
New Drug Application
Office of Regulatory Affairs
Purchaser
Regencell Bioscience Holding Limited
Research and Development
Real-World Assets
Small Business Investment Company
U.S. Securities and Exchange Commission
Smart Contracts
Securities Token Offering
Traditional Chinese Medicine
NutraCoin
User Experience
User Interface
United States of America
Limited Offering White Paper

I. EXECUTIVE SUMMARY

The following material is intended to summarize information contained elsewhere in this Limited Offering White Paper (the “White Paper”). This summary is qualified in its entirety by express reference to this White Paper and the materials referred to and contained herein. Each prospective subscriber should carefully review the entire NutraCoin White Paper on www.nutracoins.ai and all materials referred to herein and conduct his or her own due diligence before subscribing for the Tokens. NutraCoin Custom Wallet App address deploying a SC.

Welcome to the next generation of health and wellness from Golden Sunrise. Golden Sunrise dietary supplement products were created for improvement of health. It’s a seismic shift in how we approach Health, Wealth, and Helping Mankind. NutraCoin built on the blockchain with a supply of twenty-five billion (25,000,000,000) tokens, NutraCoin is set to begin fundraising to engage Golden Sunrise into a global leadership role in the centralized health and healthcare sector incorporating digital tokens for the financial company standard. Imagine a world where every health and wellness goal you achieve from Golden Sunrise dietary supplement products, gives you exclusive benefits for your overall health. NutraCoin is a thrilling fusion of a nutraceutical company, pharmaceutical company, built on the blockchain, and the use of SC to automate compliance and enforce rules etc., that is poised to dominate the five trillion (\$5,000,000,000.000.00) dollars nutraceutical and pharmaceutical market. Golden Sunrise dietary supplement products are beneficial particularly in cases where other prescription drug treatments have failed or are resistant to treatment. Golden Sunrise dietary supplement products are reshaping healthcare by using the body's own immune system and developing more personalized treatments. Join us now and be part of a New Medical Innovation revolution that is changing lives through health, wellness, and helping mankind.

THE NUTRACOIN TOKEN OFFERING IS NOT UNDERWRITTEN. THE NUTRACOIN TOKENS ARE OFFERED ON A “BEST EFFORTS” BASIS BY GOLDEN SUNRISE THROUGH ITS OFFICERS AND DIRECTORS.

THE SECURITIES TOKEN OFFERING (SECURITIES) HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY STATE SECURITIES AGENCY, NOR HAS ANY SUCH REGULATORY BODY REVIEWED THIS OFFERING WHITE PAPER FOR ACCURACY OR COMPLETENESS. BECAUSE THESE SECURITIES HAVE NOT BEEN SO REGISTERED, THERE MAY BE RESTRICTIONS ON THEIR TRANSFERABILITY OR RESALE BY AN INVESTOR. EACH PROSPECTIVE INVESTOR SHOULD PROCEED ON THE ASSUMPTION THAT HE MUST BEAR THE ECONOMIC RISKS OF THE INVESTMENT FOR AN INDEFINITE PERIOD, SINCE THE SECURITIES MAY NOT BE SOLD UNLESS, AMONG OTHER THINGS, THEY ARE SUBSEQUENTLY REGISTERED UNDER THE APPLICABLE SECURITIES ACTS, OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. GOLDEN SUNRISE IS NOT OBLIGATED TO REGISTER FOR SALE UNDER EITHER FEDERAL OR STATE SECURITIES LAWS THE TOKENS ARE PURCHASED PURSUANT HERETO, AND THE ISSUANCE OF THE TOKENS IS BEING UNDERTAKEN PURSUANT TO RULE 506 OF REGULATION D UNDER THE SECURITIES ACT. THE OFFERING PRICE OF THE SECURITIES TO WHICH THE CONFIDENTIAL TERM SHEET RELATES HAS BEEN ARBITRARILY ESTABLISHED BY GOLDEN SUNRISE AND DOES NOT NECESSARILY BEAR ANY SPECIFIC RELATION TO THE ASSETS, BOOK VALUE OR POTENTIAL EARNINGS OF GOLDEN SUNRISE OR ANY OTHER RECOGNIZED CRITERIA OF VALUE.

No person is authorized to give any information or make any representation not contained in the White Paper and any information or representation not contained herein must not be relied upon. Nothing in this White Paper should be construed as legal or tax services.

All of the information provided herein has been provided by the White Paper of Golden Sunrise. Golden Sunrise makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections, estimates, believe, expect, intend, anticipate, future plans, or forward looking assumptions or statements, as to their attainability or the accuracy and completeness of the assumptions from which they are derived, and it is expected that each prospective investor will pursue his, her, or its own independent investigation. It must be recognized that estimates of Golden Sunrise's performance are necessarily subject to a high degree of uncertainty and may materially differ from actual results.

No general solicitation or advertising in whatever form will or may be employed in the Offering of the Securities, except for this White Paper (including any amendments and supplements hereto), the exhibits hereto and documents summarized herein, or as provided for under Regulation D of the Securities Act of Year-1933. Other than Golden Sunrise's management, no one has been authorized to give any information or to make any representation with respect to Golden Sunrise or the Tokens that are not contained in this White Paper. Prospective investors should not rely on any information not contained in this White Paper.

This White Paper does not constitute an offer to sell, or a solicitation of an offer to buy, to anyone in any jurisdiction in which such offer or solicitation would be unlawful or is not authorized or in which the person making such offer or solicitation is not qualified to do so.

This White Paper does not constitute an offer if the prospective investor is not qualified under applicable Securities laws.

This Offering is made subject to withdrawal, cancellation, or modification by Golden Sunrise without notice and solely at Golden Sunrise's discretion. Golden Sunrise reserves the right to reject any subscription or to allot to any prospective investor less than the number of Tokens subscribed for by such prospective investor.

This White Paper has been prepared solely for the information of the person to whom it has been delivered by or on behalf of Golden Sunrise. Distribution of this White Paper to any person other than the prospective investor to whom this White Paper is delivered by Golden Sunrise and those persons retained to advise them with respect thereto is unauthorized. Any reproduction of this White Paper, in whole or in part, or the divulgence of any of the contents without the prior written consent of Golden Sunrise is strictly prohibited. Each prospective investor, by accepting delivery of this White Paper, agrees to return it and other documents received by them to Golden Sunrise if the prospective investor's subscription is not accepted or if the Offering is terminated.

By acceptance of this White Paper, prospective investors recognize and accept the need to conduct their own thorough investigation and due diligence before considering a purchase of the Tokens. The contents of this White Paper should not be considered to be investment, tax, or legal advice and each prospective investor should consult with their own counsel and advisors as to all matters concerning an investment in this Offering.

INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

II. INTRODUCTION

The inventiveness of Golden Sunrise is through its unique *New Medical Innovation Cellular Therapy* and is redefining healthcare and wellness with NutraCoin, a STO. With twenty-five billion (25,000,000,000) Tokens, NutraCoin powers an ATS on the FAM Tokenization Platform in the RWA for transacting Tokens from Golden Sunrise through the fluctuations in trading and the growth of income by Golden Sunrise from its powerful base. Our mission from NutraCoin token funding is for Golden Sunrise to follow through with the U.S. Regulatory Compliance. This launch is to a New Medical Innovation for dietary supplement products from an already existing pipeline of Golden Sunrise products. Golden Sunrise intends to build an administrative team of professionals, fund applications to manufacturing, other infrastructure goals, comply with the U.S. Governmental policies, and expand global health and wellness markets that are valued at five trillion (\$5,000,000,000.00) dollars in Year-2024. This broader pharmaceutical and nutraceutical market is expected to grow to eleven trillion (\$11,000,000,000.00) dollars by Year-2034. The Golden Sunrise of New Medical Innovation is to provide preventive healthcare for the aging population by enabling early diseases or conditions treatment.

About Golden Sunrise

Golden Sunrise is a dietary supplement manufacturer and marketing company involved in the development of herbal/botanical and nutraceutical products *unique* in the fields of dietary supplements. Golden Sunrise has a commitment to *safety* and to health benefits and outcomes of individuals' overall health. Overcoming anything that may hinder people from leading a healthy, and productive life is one of Golden Sunrise's utmost priorities, through the introduction of research for safe and effective dietary supplement products. Golden Sunrise treatment can be more targeted than traditional treatments, potentially reducing damage to healthy cells. Golden Sunrise Dietary Supplement Products are a relatively new approach that may be considered a form of immunotherapy. Golden Sunrise's goal is to promote quality physical health, and also improve the quality of mental health that will give fulfillment and hope to patients for a better tomorrow.

Scientific Breakthrough

Golden Sunrise New Medical Innovation is Cellular Therapy that improves the cellular structure in the body to target the aging process. Cellular Malfunction is the root cause of *Serious or Life-threatening* diseases, including *Cancer*. This approach incorporates the use of botanical/herbal constituents, and their use has been a key component in the development and effectiveness that is clinically relevant important for Real World Evidence, using approaches from the Tiêu Equation

methodology that introduces substances into living organisms which generates energy can cause cell expansion *via* thermal or temperature changes. The ability of particles to exhibit wave-like properties is explained by the fundamental principle of Wave-Particle Duality. In Quantum Mechanics, particularly Quantum tunneling, affect cellular functions in key biological processes such as enzymatic reactions DNA and repair.

Golden Sunrise Prior Investors

Golden Sunrise Nutraceutical, Inc. began operation in January; Year-2017 Mr. Loeffler and another provided for early funding and received one hundred (100%) percent of the Shares for the Voting Stock. No other investment was received for this stock class.

On May 10, 2017 Golden Sunrise Nutraceutical, Inc. filed with the SEC CIK No.: 0001705521 under Regulation D Rule 506(b) Jurisdiction of Corporation DELAWARE.

In Year-2017 Golden Sunrise fundraising consists of seventy (70) investors with accredited investors and non-accredited investors and raised a total of one million (\$1,000,000.00) dollars.

Golden Sunrise Goal

Golden Sunrise is well positioned to compete in the healthcare and wellness marketplace. R&D has achieved the New Medical Innovation that will benefit the healthcare industry. On March 22, 2019 Golden Sunrise validated the safety and effectiveness of its line of dietary supplement products with patient medical report results. The patient report medical results magnify that Golden Sunrise will quickly gain market acceptance and outperform competitors now, and in the future. Golden Sunrise and its dedicated staff, dream of a world where every person in this global community is healthy and may pursue their dreams without illness for them or their loved ones. NutraCoin isn't just currency; it's the heartbeat of a global health revolution, connecting users, brands, and investors in a vibrant ecosystem.

The main difference is that Golden Sunrise brings decades of expertise in New Medical Innovation, Regulatory Compliance, Healthcare, Dietary Supplement Products, and is now incorporating STO financial funding with blockchain technology. Our commitment to quality and transparency sets us apart, making NutraCoin the trusted choice for New Medical Innovation.

Medically Underserved Population

Golden Sunrise will consider establishing a policy of making two (2%) percent of their products available free to the entire medically underserved population.

Golden Sunrise Advantages

The advantage of this New Medical Innovation is that taking Golden Sunrise dietary supplement products can improve overall health which in turn can provide longevity, prevent illnesses, and give quality-of-life to those taking Golden Sunrise products. Patients can benefit from the treatments of Golden Sunrise products for any conditions being treated.

Real-World Evidence provides Real-World Value gathered from actual patient medical records.

Compiling observations and administration of Golden Sunrise products should always be under the supervision of a licensed physician, registered nurse, and/or medical specialists in the medical field. Recommendations for Golden Sunrise products are based on the following criteria:

Protocol, Medical evaluation, assessment, diagnoses, monitoring, and medical report results of the patient. Evidence-Based Care is a set of principles and methods intended to ensure that to the greatest extent possible that best clinical judgments or medical decisions are made.

On March 22, 2019, Inspector from the FDA ORA division, inspected the Golden Sunrise facility in PORTERVILLE California. FDA classified all Golden Sunrise dietary supplement products and FDA published under section FDA Compliance Dashboards <https://datadashboard.fda.gov/oii/cd/inspections.htm>.

On November 21, 2024, Inspector from the FDA Consumer Safety Officer division, inspected the Golden Sunrise facility in PORTERVILLE California * U.S.A.

On December 16, 2025, Inspector from FDA from Office of Human Food Inspectorate West 2, Office of Inspections and Investigations division, inspected the Golden Sunrise facility in PORTERVILLE California * U.S.A.

Golden Sunrise Disadvantages

Golden Sunrise faces skepticism from healthcare professionals due to its product line being dietary supplement products. Many medical professionals received little training in herbal or alternative medicine. This knowledge gap makes it difficult for them to have informed conversations with patients, nor can they confidently assess the use of Golden Sunrise dietary supplement products. Some patients fear being criticized by their doctors for using supplements, while others simply don't see the dietary supplements as important enough to mention.

Tieu Equation

The Novelty of the invention of new medicine was created by Mr. Tieu and had its background in science encompassing the disciplines of Quantum Biology, Quantum Mechanics, Chemistry, etc. In the realm of physics, all of nature and its effects are governed by physics: The Nature of the Universe and Humans are connected. Under Artificial Intelligence

(AI) Overview:

https://www.google.com/search?q=tieu+equation&sca_esv=acaa26f93be3293b&ei=u3lnaLTqL9LakPIPh_is8Qw&ved=0ahUKEwj0s4bKzqKOAxVSLUQIHQc8K84Q4dUDCBI&uact=5&oq=tieu+equation&gs_lp=Egxnd3Mtd2l6LXNlcnAiDXRpZXUgZXF1YXRpb24yBRAAGIAEMgUQABiABDIFEAAyGAAQyCBAAGIAEGKIEGgQABiABBiiBDIIEAAyGAAQYogQyCBAAGKIEGIkFSNYIUIYLWK0ZcAF4AZABAJgBYKABmwWqAQE5uAEDyAEA-AEBmAIKoALIBcICChAAGLADGNYEGEfCAgUQIRigAcICBRAhGKsCwgIFECEYnwXCAgYQABgWGB7CAgUQABjvBZgDAIgGAZAGApIHazkuMaAHyCKyBwM4LjG4B94FwgcFMC4yLjjIByo&sclient=gws-wiz-serp

Golden Sunrise Regulatory History

In Year-2020, Golden Sunrise became the subject of federal regulatory scrutiny for allegedly making unsubstantiated health claims regarding its products. Legal actions by the FTC and the DOJ led to enforcement measures and subsequent challenges in business operations.

Golden Sunrise Solution

FIRST; Criminal case No.: 1:20-cr-00109-BAM-1 Magistrate Judge Barbara A. McAuliffe: SENTENCEING held on June 12, 2024 for Huu Tieu.... Oral, motion by the government to

dismiss the Indictment was **GRANTED**. Government waived right to seek forfeiture. CASE CLOSED.

SECOND; Golden Sunrise and Mr. Tieu have overwhelming factual evidence to prove their case and show that Golden Sunrise and Mr. Tieu complied with the U.S. Government's requirements.

THIRD; On February 19, 2019 through March 22, 2019 FDA Investigator, inspected the Golden Sunrise facilities in PORTERVILLE California. It focused on cancer patient treatment under the care of physician with KemoHerbs. A total forty-two (42) patients have been treated since April; 2017. After an inspection Form FDA-483 Inspectional Observations, was not issued during the current inspection. In Establishment Inspection Report FEI No.: 30123237979 Investigator John A. GONZALEZ (Mr. Gonzalez) stated "*I told Mr. Tieu that I would submit all records collected for a review and classification of his products*" and FDA Classified Golden Sunrise Nutraceutical products as "DRUGS" on March 22, 2019.

FOURTH; On November 05, 2024 through November 21, 2024 FDA Inspector, Consumer Safety Officer, inspected or investigated the Golden Sunrise facilities in PORTERVILLE California. FDA Affidavit stating that – *The dietary supplements are given to treat patients in various stages of Serious or Life-threatening diseases, including different stages of Cancer.*

FIFTH; Civil case No.: 1:20-cv-01060-DJC-SKO on October 20, 2025 Judge Calabretta ordered in favor of the FTC against Golden Sunrise, Mr. Tieu, and Stephen R. MEIS Motion for Summary Judgment and Permanent Injunction was **GRANTED**. Golden Sunrise is still allowed to continue doing business without paying a civil penalty to the FTC and without returning money to consumers. CASE CLOSED.

SIXTH; On December 02, 2025 through December 16, 2025 an FDA Inspector/Investigator from Office of Human Food Inspectorate West 2, Office of Inspections and Investigations division, inspected the Golden Sunrise facilities in PORTERVILLE California. An FDA Affidavit stating that – *Golden Sunrise's customers consist of medical groups and doctors throughout the United States which purchase the Golden Sunrise products via healthcare plans and using Value-Based Healthcare incentives for physicians to treat patients with chronic conditions such as various cancer or other various stages of Serious or Life-threatening diseases* (Golden Sunrise Nutraceutical products are intended to diagnoses, cure, mitigate, treat, or prevent diseases) were signed on December 16, 2025. After an inspection FDA issued Form FDA-483 lists Inspectional Observations of objectionable conditions found during an FDA inspection, indicating potential violations of the FD&C Act or Regulations, requiring prompt corrective action from Golden Sunrise, with common issues.

SEVENTH; On January 01, 2026 Golden Sunrise responded to FDA Human Foods Program – Office of Compliance and Enforcement with a detailed, written plan addressing each observation, timelines, and all supported by documentation to avoid escalating FDA Actions like a Warning Letters, product recalls, withholding products Postmarketing, or operational shutdown. On January 01, 2026 the FDA Human Foods Program, Office of Compliance Enforcement acknowledges the receipt Golden Sunrise email, in response to the Form FDA-483, Inspectional

Observations. FDA will be reviewed and will be made part of the official records for Golden Sunrise facility.

III. TOKENIZATION

Real-World Assets (RWA)

Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc. are the RWA of NutraCoin token. The RWA for Golden Sunrise are the following:

- Golden Sunrise New Medical Innovation Cellular Therapy Breakthrough – Treatment and Cellular Therapy, Nutraceuticals, and Dietary Supplements. Cancer, Serious or Life-threatening diseases, and Chronic conditions present a Multi-Trillion Dollar Investment Opportunity;
- Golden Sunrise has received a valuation appraised by Eqvista and its Final Report on May 20, 2025 (**Exhibit “A”**);
- Create a NutraCoin Custom Wallet App for involving secure key management and compliance with financial regulations;
- Golden Sunrise’s dietary supplement products are based on patient medical report results and evaluated by the Medicare, Medical audits are performed by the experts, Anthem BlueCross on November 13, 2020, on June 24, 2020 UnitedHealthcare, Samaritan Ministries on March 23, 2019, and on January 18, 2025 Cigna Group also, agreed payment for chronic diseases;
- Billing Code M0075 Cellular Therapy;
- Golden Sunrise submitted ImunStem, filed three (3) NDAs No.: 204701 on January 07, 2013, on November 18, 2018, and on April 03, 2020;
- Golden Sunrise dietary supplement products have been evaluated by the FDA and are the following; Aktiffvate, AnterFerron-1, AnterFerron-2, AppetiteHerb, AwayHunger, AwayHurt, C-Nite, CrProtein, DetoxHerb-1, DetoxHerb-2, DetoxHerb-RN, DetoxHerb-PI, HormonHerb, HyProtein-1, HyProtein-2, HyProtein-3, HyProtein-4, ImunStem, LunCov-1, LunCov-2, LyProtein, MaoPressure, NueRon, NutraHerb, and Vietneze-40;
- On March 22, 2019 FDA have been evaluated and classified Golden Sunrise Nutraceutical products as “DRUGS”;
- On November 21, 2024 issued Form FDA-463a Affidavit stating that “*The dietary supplement are given to treat patients in various stages of serious or life-threatening disease including different stage of cancer*”;
- On December 16, 2025 issued Form FDA-463a Affidavit stating that “*Golden Sunrise’s customers consist of medical groups and doctors throughout the United States which purchase the Golden Sunrise’s products via healthcare plans and using Value-Based Healthcare incentives for physicians to treat patients with chronic conditions such as various cancer or other various stages of Serious or Life-threatening diseases*”. FDA functions to ensure Golden Sunrise dietary supplement products that are available to medical groups, doctors, health systems, patients are safe, effective, and of high quality. When properly implemented, the requirements help ensure Golden Sunrise dietary supplement products are safe, effective, and meet regulatory standards;
- Golden Sunrise products Secret Proprietary New Medical Innovation Therapeutic Medicines Cellular Therapy Property;
- Aktiffvate, AwayHunger, ImunStem, NutraCoin logo, and Golden Sunrise logo are Trademarks by the U.S. Patent and Trademark Office;
- The burn rate of one billion (\$1,000,000,000.00) dollars over five (5) years, Golden Sunrise would need to spend an average of two hundred million (\$200,000,000.00) dollars per year,

approximately. This is a calculation of a company's gross burn rate, and does not factor in any revenue Golden Sunrise might generate;

- The property at 219 North E Street, PORTERVILLE California is owned by Golden Sunrise Nutraceutical, Inc.;
- Honda Odyssey Year-2022;
- Retain a loan for Golden Sunrise Growth and Expansion. In November 22, 2024 the loan amount was seventy-five thousand (\$75,000.00) dollars. The schedule for payoff is December 01, 2026 to Mid Valley Financial. These properties were made available as collateral for Golden Sunrise benefit to leverage funds for the expansion of the company; and
- Retain a loan for Golden Sunrise Growth and Expansion. In December 18, 2025 the loan amount was twenty thousand (\$20,000.00) dollars.

IV. ADVISORS

The professionals identified below have roles in various fields, such as personal financial, legal, and other advisor functions. Their function is to share expertise to help Golden Sunrise and achieve our goal.

Banking Advisors: Wells Fargo
815 W. Henderson
PORTERVILLE, CA 93257

Chase Bank Advisor
1079 E. Prosperity Avenue
TULARE, CA 93274

Valuation Advisor: Eqvista, Inc.
14A, Spear Street, #280
SAN FRANCISCO, CA 94105

Financial Advisor: Apptunix Technologies Pvt., Ltd.
3rd Floor, C-127, Phase-8, Industrial Area, Sector 73,
Sahibzada Ajit Singh Nagar, Punjab 160071 * India

Medical Advisor: Oakview Medical Group
1011 N. Demaree Street
VISALIA, CA 93291

Contract Manufacturers: WePackItAll
2745 Huntington Drive
DURATE, CA 91010

PureNSM
1065 Bay Blvd. D
CHULA VISTA, CA 91911

Legal and Counsel: Simon TANG
Security Attorney
WinWin Law, PLLC

Thoughts to Paper
Patent and Trademark
20251 Century Blvd., #140
GERMANTOWN, MD 20874

V. COMPANY OVERVIEW

Golden Sunrise Nutraceutical, Inc. began operations in January; 2017, with the purpose to be a Manufacturing and Marketing Company, of pharmaceutical and nutraceutical products used in the health care market. The Company's legal structure was formed as a "C" corporation under the laws of the State of Delaware on November; 2016, EIN No.: 81-4810894, and DUNS No.: 078313240. Its principal offices are presently located at 219 North E Street, PORTERVILLE California 93257. The Company's telephone number is 1.559.781.0658, fax number 1.559.615.1268, email address info@goldensunrisenutraceutical.com, and website www.goldensunrisenutraceutical.com.

Administrative

Martin F. LOEFFLER..... Chief Executive Officer and President
Huu S. TIEU..... Chief Science Officer and Regulatory Compliance
Rachel M. AYALA..... Chief Financial Officer
Sonja I. FONTANA..... Chief Medical Officer
Edgar AYALA..... Clinical Nurse Consultant
Jamie GENTRY..... Healthcare Billing Officer
Fatima-Ezzahra AZIAR..... Project Manager
Bilal AKHYAR..... Strategy & Digital Transformation

Martin F. LOEFFLER (Mr. Loeffler) has always enjoyed the research of plants and plant biology. Mr. Loeffler studied in agriculture and received his AS Degree from the College of the Sequoias in Agriculture Year-1984 as an undergraduate. Mr. Loeffler pursued an agricultural career but have leaned towards research of plant based science and the constituents contained in a variety of living organisms. Mr. Loeffler's focus has been to research the effects of defined elements contained in living organisms and their effects on human overall health. Mr. Loeffler's research has led to the aid and development of a New Medical Innovation that has a beneficial outcome for patients suffering from Serious or Life-threatening conditions, including Cancer.

Huu S. TIEU (Mr. Tieu) created a New Medical Innovation Cellular Therapy which has its background in science encompassing the disciplines Quantum Biology, Quantum Mechanics, Chemistry, etc. This is the foundation of the **Tieu Equation**. In the realm of physics, all of nature and its effects are governed by Physics, Chemistry, and Biology.

Rachel M. AYALA (Ms. Ayala) Ms. Ayala graduated from the Licensed Vocational Nursing Program at Hartnell College. Ms. Ayala engaged as a staff member Salinas Valley Memorial Hospital for six years. Ms. Ayala worked for the Tulare County Health and Human Services Department as a Human Resources Manager for eleven years. Ms. Ayala was engaged at Golden

Sunrise Nutraceutical under the direction of the Chief Financial Officer (CFO) since Year-2012 and became CFO in Year-2023 which she holds the title and position to this present day.

Sonja I. FONTANA (Mrs. Fontana) Doctorate prepared Family Nurse Practitioner, specializing in primary care practice, individualized Holistic practice, and preventative care applying clinical research into practice. Mrs. Fontana has a transformer leadership which identifies the best qualities in individuals and utilizes them to their fullest potential.

Edgar AYALA (Mr. Ayala) has dedicated Registered Nurse with over twenty years of clinical experience, specializing in Trauma, Emergency, and Intensive Care Units. Mr. Ayala journey into the medical field began during a life-changing experience in Year-1999. Mr. Ayala has developed a strong clinical foundation through his work in various roles, including as a Clinical Nurse Consultant and Pharmaceuticals representative. In these capacities, Mr. Ayala collaborated with Golden Sunrise Nutraceutical on research aimed at treating Serious or Life-threatening conditions, including cancer patients.

Jamie GENTRY (Ms. Gentry) Ms. Gentry has a versatile employment background ranging from agricultural research to health related sectors. Ms. Gentry experience with insurance claims management stemmed from her employment with Blue Shield of California from Year-2001 through Year-2003. Ms. Gentry graduated from Five Branches University in Year-2025 with her Doctorate in Traditional Chinese Medicine. As an advocate for patient dignity, safety, and access to high quality health care, she pursued a post-doctorate in Acupuncture and Oriental Medicine to extend her experience and research while she treats patients in various regions of California.

Fatima-Ezzahra AZIAR (Mrs. Aziar) is passionate about management and international trade, preparing and completing sales agreements. Mrs. Aziar received her Masters Degree from Ibegis Business School in Casablanca Year-2017. Mrs. Aziar provides a rigorous, well-organized, and determined approach to any challenge. Mrs. Aziar is able to cultivate and deepen relationships with customers and companies. Mrs. Aziar is ready to put her knowledge and skills to work in a demanding position offering career development and long-term success. Mrs. Aziar speaks fluently in Arabic, English, French, Spanish, and Turkish.

Bilal AKHYAR (Mr. Akhyar) has been collaborated with business partners across Retail and Telecom, Courier Services to implement data-driven change, improve operational efficiency, ensure strategic alignment across stakeholders. Mr. Akhyar received his Maters Degree from University of Aberdeen Year-2015. Mr. Akhyar has led initiatives in data governance, operating model redesign, retail transformation, and customer services journey development. Mr. Akhyar has delivered success in his field through measurable business outcomes.

VI. REQUIREMENTS FOR PURCHASERS

Accredited Investors

On June 20, 2025 Golden Sunrise Nutraceutical, Inc. filed with SEC CIK No.: 0001705521 under Regulation D Rule 506(c) Jurisdiction of Corporation DELAWARE.

Individuals (i.e., natural persons) may qualify as Accredited Investors if they meet any of the following wealth, income, or financial sophistication. In summary, a prospective investor will qualify as an “Accredited Investor” if he, she, or it meets any one (1) of the following criteria:

- Any natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase, exceeds one million (\$1,000,000.00) dollars;
- income over two hundred thousand (\$200,000.00) dollars (individually) or three hundred thousand (\$300,000.00) dollars (with spouse or partner) in each of prior two (2) years, and reasonably expects the same for the current year;
- any bank as defined in Section 3(a)(2) of the Act, or any saving and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to Section fifteen (15) of the Securities and Exchange Act of 1934 (the “Exchange Act”); any insurance company as defined in Section 2(13) of the Exchange Act; any investment company registered under the Investment Company Act of Year-1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company (SBIC) licensed by the U.S.A. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of Year-1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of five million (\$5,000,00.00) dollars; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of Year-1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, saving and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of five million (\$5,000,000.00) dollars or, if a self-directed plan, with investment decisions made solely by persons who are Accredited Investors;
- any private business development company as defined in Section 202(a)(22) of the Investment Advisors Act of Year-1940;
- any organization described in Section 501(c)(3)(d) of the IRS, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the Securities offered, with total assets in excess of five million (\$5,000,000.00) dollars;
- any director or executive officer, or general partner of the issuer of the Securities being sold, any director, executive officer, or general partner of that issuer;
- any trust, with total assets in excess of five million (\$5,000,000.00) dollars, not formed for the specific purpose of acquiring the Securities offered, whose purchase is directed by a sophisticated person as described in Section 506(b)(2)(ii) of Regulation D adopted under the Act; and
- any entity in which all the equity owners are Accredited Investors.

Rule 144: Selling Restricted and Control Securities

Selling Restricted or Control Securities, Golden Sunrise must follow SEC Rule 144, which often requires holding the NutraCoin Tokens for a certain period six to twelve (6–12) months and adhering to volume/manner of sale restrictions, which requires Golden Sunrise approval and rely on exemptions like Regulation D for initial purchase and Rule 144 for resale of the following criteria:

- **Holding Period:** Before Golden Sunrise may sell any Restricted Securities in the marketplace, you must hold them for a certain period of time. If the company that issued the Securities is a “Reporting Company” in that it is subject to the reporting requirements of the Securities Exchange Act of Year-1934, then you must hold the Securities for at least six (6) months. If the issuer of the Securities is not subject to the reporting requirements, then you must hold the Securities for at least one (1) year. The relevant holding period begins when

the Securities were bought and fully paid for. The holding period only applies to Restricted Securities. Because Securities acquired in the public market are not restricted, there is no holding period for an affiliate who purchases Securities of the issuer in the marketplace. But the resale of an affiliate's Tokens as control Securities is subject to the other conditions of the rule;

- **Current Public Information:** There must be adequate current information about the issuing company publicly available before the sale can be made. For reporting companies, this generally means that the companies have complied with the periodic reporting requirements of the Securities Exchange Act of Year-1934. For non-reporting companies, this means that certain company information, including information regarding the nature of its business, the identity of its Officers and Directors, and its financial statements, is publicly available;
- **Trading Volume Formula:** If you are an affiliate, the number of equity Securities you may sell during any three (3) months period cannot exceed the greater of one (1%) percent of the outstanding Tokens of the same class being sold, or if the class is listed on a blockchain, the greater of one (1%) percent or the average reported weekly trading volume during the four (4) weeks preceding the filing of a notice of sale on Form 144;
- **Ordinary Brokerage Transactions:** The sales must be handled in all respects as routine trading transactions, and brokers may not receive more than a normal commission. Neither the seller nor the broker can solicit orders to buy the Securities; and
- **Filing a Notice of Proposed Sale with the SEC:** Golden Sunrise must file a notice with the SEC on Form 144 if the sale involves more than five thousand (5,000) NutraCoin Tokens or the aggregate dollar amount is greater than fifty thousand (\$50,000) dollars in any three (3) months period.

Foreign Investors

SEC Rule 144 under the Securities Act of Year-1933: Selling Restricted Securities, Control Securities, and Golden Sunrise must File Form 144 of the following criteria:

- **Holding Period:** Before Golden Sunrise may sell any Restricted Securities in the marketplace, you must hold them for a certain period of time. If the company that issued the Securities is a “Reporting Company” in that it is subject to the reporting requirements of the Securities Exchange Act of Year-1934, then you must hold the Securities for at least six (6) months. If the issuer of the Securities is not subject to the reporting requirements, then you must hold the Securities for at least one (1) year. The relevant holding period begins when the Securities were bought and fully paid for. The holding period only applies to Restricted Securities. Because Securities acquired in the public market are not restricted, there is no holding period for an affiliate who purchases Securities of the issuer in the marketplace. But the resale of an affiliate's Tokens as control Securities is subject to the other conditions of the rule;
- **Current Public Information:** There must be adequate current information about the issuing company publicly available before the sale can be made. For reporting companies, this generally means that the companies have complied with the periodic reporting requirements of the Securities Exchange Act of Year-1934. For non-reporting companies, this means that certain company information, including information regarding the nature of its business, the identity of its Officers and Directors, and its financial statements, is publicly available;
- **Trading Volume Formula:** If you are an affiliate, the number of equity Securities you may sell during any three (3) months period cannot exceed the greater of one (1%) percent of the outstanding tokens of the same class being sold, or if the class is listed on a blockchain, the

greater of one (1%) percent or the average reported weekly trading volume during the four (4) weeks preceding the filing of a notice of sale on Form 144;

- **Ordinary Brokerage Transactions:** The sales must be handled in all respects as routine trading transactions, and brokers may not receive more than a normal commission. Neither the seller nor the broker can solicit orders to buy the Securities; and
- **Filing a Notice of Proposed Sale with the SEC:** Golden Sunrise must file a notice with the SEC on Form 144 if the sale involves more than five thousand (5,000) NutraCoin tokens or the aggregate dollar amount is greater than fifty thousand (\$50,000) dollars in any three (3) months period.

VII. PROBLEM STATEMENT

The nutraceutical and pharmaceutical industries are at a crossroads. Despite its five trillion (\$5,000,000,000.000.00) dollars valuation, it is riddled with challenges; opaque supply chains breed distrust, counterfeit products harm consumers, centralized platforms fail to motivate. Users crave rewards, but apps like MyFitnessPal offer no real incentives, leaving engagement stagnant. Meanwhile, forty (40%) percent of consumers distrust dietary supplement products sourcing (Nielsen in Year-2024) and counterfeits cost brands billions annually.

Key Industry Pain Points

- **Counterfeit Products:** Fake dietary supplement products undermine safety and effectiveness, and without FDA review and classification.

VIII. TARGET MARKET

The Market for Cancer and Chronic Disease Treatments Opportunity

The global cancer treatment Cellular Therapy market size is estimated at US\$240-billion in Year-2025, and is expected to reach US\$400-billion by Year-2030.

The Serious or Life-threatening conditions and diseases or Chronic Diseases Management Cellular Therapy market size is estimated at US\$750-billion in Year-2025, and is expected to reach US\$1.1-trillion by Year-2029.

The Market for Cancer, Serious or Life-threatening Diseases, and Chronic Conditions Treatments Opportunity

Treatments for Cancer, Serious or Life-threatening diseases, and chronic conditions have immense economic value, with studies suggesting slowing aging, by reducing disease, and improving healthspan as following:

- **One (1) Extra Year of Life Expectancy:** Value at approximately US\$38-trillion.
- **Ten (10) Extra Years of Life Expectancy:** Value at approximately US\$367-trillion.

Marketing Plan

Golden Sunrise Research and Development has achieved the New Medical Innovation Cellular Therapy that will benefit the healthcare industry. NutraCoin is set to dominate its market, and Golden Sunrise is well positioned to compete in the competitive marketplace. Our timing is impeccable; rising crypto adoption meets comprehensive healthcare awareness.

Golden Sunrise's success will be particularly dependent upon Mr. Loeffler, President, Mr. Tieu, Chief Science Officer, and Mrs. Fontana, Chief Medical Officer of Golden Sunrise in the development of Golden Sunrise operations, and business ventures.

IX. MARKET TRENDS AND COMPETITIVE ANALYSIS

The nutraceutical industry itself is indeed a booming market driven by increasing consumer interest in preventive health/wellness and NutraCoin is well positioned. Driven by a healthcare conscious global population, the market is projected to hit eight trillion (\$8,000,000,000,000.00) dollars by Year-2032 (MarketWatch in the Year-2025). Trends like personalized nutrition, botanical/herbal and dietary supplement products, and blockchain transparency are reshaping the landscape, and NutraCoin is at the forefront.

Key Market Trends

- **Personalized Health and Wellness:** Sixty (60%) percent of consumers prefer tailored dietary supplement products (Mintel in Year-2024).
- **Blockchain Adoption:** Thirty (30%) percent of health brands and healthcare market is growing at a high rate, with various application gaining traction for blockchain integration in healthcare by Year-2027 (Deloitte in Year-2024) – NutraCoin is ahead of the curve.

X. RISKS AND MITIGATION

Risks Factors

Please see under section “XIV. RISKS FACTORS” which include reliance on one (1) main distributor, reliance on management, and unanticipated obstacles to execution of the NutraCoin White Paper.

Forward Looking Information

Some of the statements contained in this White Paper, including information incorporated by reference, discuss future expectations, or state other forward-looking information. Those statements are subject to unknown risks, uncertainties and other factors, several of which are beyond Golden Sunrise's control that could cause the actual results to differ materially from those contemplated by the statements or force majeure. The forward-looking information is based on various factors and was derived using numerous assumptions. In light of the risks, assumptions, and uncertainties involved, there can be no assurance that the forward-looking information contained in this White Paper will in fact transpire or prove to be accurate.

Important factors that may cause the actual results to differ from those expressed within include, but are not limited to, the following:

- The success or failure of Golden Sunrise's efforts to successfully market the website and product matrix as scheduled;
- Golden Sunrise's ability to attract, build, and maintain a customer base;
- Golden Sunrise's ability to attract and retain high-quality employees;
- the effect of changing economic conditions;
- the ability of Golden Sunrise to obtain adequate debt financing if only a fraction of this STO is sold; and
- other risks which are described under “RISK FACTORS” and which may be described in future communications to shareholders. Golden Sunrise makes no representation and

undertakes no obligation to update the forward-looking information to reflect actual results or changes in assumptions or other that could affect those statements.

XI. LEGAL AND COMPLIANCE

NutraCoin is a STO, compliant with SEC Regulation D 506(c) and engage counsel for FDA compliance. All sales are audited, funds secured in multi-signature wallets – transparency guaranteed.

Compliance Framework

Includes GDPR compliant data privacy, regular legal reviews, KYC/AML, and anti-money laundering checks – NutraCoin is as safe as it is existing.

XII. FINANCIAL FORECASTS & INCOME

Sales Income

• Income Year-2023.....	<u>\$ 14,300.00</u>
• Income Year-2024.....	<u>16,275.00</u>
• Current Income Year-2025	\$ 12,527.06
Consumer Deposited	<u>25,000.00</u>
Total Income on December 31, 2025.....	<u>37,527.06</u>

Medicare and Private Insurance receivable coverage between
November 01, 2024 thru December 31, 2025..... \$ 300,000.00

XIII. OVERVIEW OF VALUATION

Golden Sunrise has significant value based on the following criteria:

- Breakthrough New Medical Innovation botanical/herbal dietary supplement treats overall health. Treatment and Therapies of Cancer, Serious or Life-threatening diseases, and chronic conditions Products, Nutraceuticals, and Dietary Supplements.
- FDA Establishment Inspection Report FEI No.: 3012327979 Golden Sunrise products on March 22, 2019;
- On February 22, 2019, FDA Investigator stating that – *I told Mr. Tieu that I would submit all records collected for a review and classification of his products;*
- On December 21, 2024, FDA Affidavit stating that – *The dietary supplements are given to treat patients in various stages of Serious or Life-threatening diseases, including different stages of Cancer;*
- On December 16, 2025, FDA Affidavit stating that – *Golden Sunrise’s customers consist of medical groups and doctors throughout the United States which purchase the Golden Sunrise products via healthcare plans and using Value-Based Healthcare incentives for physicians to treat patients with chronic conditions such as various cancer or other various stages of Serious or Life-threatening diseases;*
- Medicare and health insurance companies agreed on payment in Value-Based Healthcare to Golden Sunrise products.
- **Tieu Equation** under AI Overview
https://www.google.com/search?q=tieu+equation&sca_esv=acaa26f93be3293b&ei=u3lnaLT

[qL9LakPIPh_is8Qw&ved=0ahUKEwj0s4bKzqKOAxVSLUQIHQc8K84Q4dUDCBI&uact=5&oq=tieu+equation&gs_lp=Egxnd3Mtd2l6LXNlcnAiDXRpZXUgZXF1YXRpb24yBRAAGIAEMgUQABiABDIFEAAygAQyCBAAGIAEGKIEMggQABiABBiiBDIIIEAAygAQYoQyCBAAGKIEGikFSNYIUIYLWK0ZcAF4AZABAjgBYKABmwWqAQE5uAEDyAEA-AEBmAIKoALIBcICChAAGLADGNYEGEfCAGUQIRigAcICBRAhGKsCwgIFECEYnwXCAGYQABgWGB7CAGUQABjvBZgDAIgGAZAGApIHAzkuMaAHyCKyBwM4LjG4B94FwgcFMC4yLjjIByo&sclient=gws-wiz-serp](https://www.fda.gov/oc/ohrt/2025-05-20-golden-sunrise-valuation-report)

On May 20, 2025, in a valuation by Eqvista. Eqvista has utilized the Income Approach with exit multiples to determine the Market Value of Golden Sunrise’s equity interest of seventeen billion three hundred thirty-five million five hundred eighty-eight thousand U.S. (US\$17,335,588,000.00) dollars considering its growth prospects, inherent risks.

The reported analyses, opinions, and conclusions are limited only by the reported assumptions and limiting conditions and are our personal, impartial, and unbiased professional analyses, opinions, and conclusions.

On December 16, 2025 FDA Inspector has requested Golden Sunrise to show its procedures for the disposal of any raw materials that have past it’s has expiration date. Golden Sunrise will voluntarily dispose of any raw materials that have pasted the expiration date on their labels.

Valuation Total Liabilities and Equity

(In USD)	As of December 31, 2025
Total Non-Current Liabilities	95,000
Total Liabilities	95,000
Equity	200,678,607,000
Total Liabilities and Equity	200,678,682,000

Golden Sunrise has twenty-four thousand (\$24,000.00) dollars in cash and ninety-five thousand (\$95,000.00) dollars in debt.

Cash and Debt

(In U.S.D.)	As of December 31, 2025
Total Cash	24,000
Total Debt	95,000

Top-Selling Cancer Drugs with Billion Dollar Revenues

Based on Year-2024 sales data, the top selling cancer drugs are primarily immunotherapies and targeted therapies for various Cancers. These prescription drugs have generated billion-dollar revenues as following:

- **Pembrolizumab:** This immune checkpoint inhibitor treats numerous cancer types, including melanoma, and non-small cell lung cancer. In Year-2024 it was the best-selling cancer drug, with sales of nearly thirty billion (\$30,000,000,000.00) dollars.
- **Paratumumab:** A monoclonal antibody that targets CD38, which is highly expressed on the surface of multiple myeloma cells. It had Year-2024 revenues of eleven billion (\$11,000,000,000.00) dollars.
- **Nivolumab:** A PD-1 Inhibitor is used for several cancers, including melanoma, lung, and renal carcinoma. It is often used for serious conditions and had Year-2023 sales exceeding ten billion (\$10,000,000,000.00) dollars.

- **Osimertinib:** This targeted therapy is for certain types of non-small cell lung cancer with specific genetic mutations. Its Year-2022 global sales were five billion (\$5,000,000,000.00) dollars.
- **Ibrutinib:** This BTK inhibitor is used for several blood cancers, including chronic lymphocytic leukemia, and mantle cell lymphoma. Its Year-2023 sales were seven billion (\$7,000,000,000.00) dollars.
- **Lenalidomide:** A therapy for multiple myeloma and myelodysplastic syndromes, Revlimid had Year-2022 of thirteen billion (\$13,000,000,000.00) dollars.
- **Palbociclib:** CDK 4/6 is used for advanced breast cancer. It brought on five billion (\$5,000,000,000.00) dollars in Year-2022.
- **Enzalutamide:** A prostate cancer treatment had Year-2023 sales of nearly six billion (\$6,000,000,000.00) dollars.
- **Bevacizumab:** This drug treats various cancers, including colorectal, lung, and glioblastoma. Though older, it was still a top seller in Year-2022, with global sales of two billion (\$2,000,000,000.00) dollars.

Traditional Chinese Medicine Value in Multi-Billion Dollars

On June 16, 2025 RBHL trades under the stock ticker RGC on the NASDAQ Composite Index stock exchange, a company focused on TCM, had a market value of approximately thirty billion (\$30,000,000,000.00) dollars, despite having no revenue, having no New Medical Innovation Breakthrough, having no FDA approval process nor filed for any regulatory approvals of its TCM formulas, and not having any patents or pending patent applications, including no Medicare or insurance payment.

The Cellular Therapy Sector Potential is Multi-Trillion Dollars

Atos Labs is a major biotechnology company focused on researching Cellular Reprogramming and Rejuvenation, aiming to reverse aging, disease, and injury by restoring cell health, with goals of developing life extension therapies and rejuvenating organ.

NewLimit, Inc. is a biotechnology company focusing on researching extending human longevity by reversing Cellular aging through Epigenetic Reprogramming and Healthspan. The company aims to develop treatment that could eventually become a multi-trillion dollar industry, though it is currently in the research phase.

Retro Biosciences focusing on researching extending ten (10) years longer (healthy human lifespan), with plans to use Artificial Intelligence to accelerate drug discovery for aging. The company also uses modular labs made from shipping containers and aims for rapid clinical trials in areas like Cellular Reprogramming, Hematopoietic Stem Cells, Autophagy Enhancement, Microglia Therapeutics, and Tissue Reprogramming.

The above companies are targeting to aging slow down chronic diseases (heart disease, cancer, and Serious or Life-threatening conditions) at their roots, preventing massive healthcare costs. A massive demand for solutions that support extended healthy living, creating a huge market.

XIV. RISK FACTORS

Investing in NutraCoin's (GSN) tokens is very risky. You should be able to bear a complete loss of your investment. You should carefully consider the following factors, among others.

Development Stage Business

Golden Sunrise commenced operations in January, 2017 and is organized as a C corporation under the laws of the State of Delaware. Accordingly, Golden Sunrise has only a limited history upon which an evaluation of its prospects and future performance can be made. Golden Sunrise's proposed operations are subject to all business risks associated with new enterprises. The likelihood of Golden Sunrise's success must be considered in light of the problems, governmental policy shifts, expenses, difficulties, complications, and delays frequently encountered in connection with the expansion of a business, operation in a competitive industry, and the continued development of advertising, promotions, and a corresponding customer base. There is a possibility that Golden Sunrise could sustain losses in the future. There can be no assurances that Golden Sunrise will even operate profitably.

Inadequacy of Funds

Gross offering proceeds of a minimum of one hundred million (\$100,000,000.00) dollars and a maximum of one billion (\$1,000,000,000.00) dollars may be realized. Management believes that such proceeds will capitalize and sustain Golden Sunrise sufficiently to allow for: the continued development and improvement of the website, the implementation of a marketing campaign, and distribution of Golden Sunrise's products for a certain period of time. If only a fraction of this token offering is sold, or if certain assumptions contained in Management's White Paper prove to be incorrect, Golden Sunrise may have inadequate funds to fully develop its business and may need debt financing or other capital investment to fully implement.

Dependence on Management

In the early stages of development Golden Sunrise's business will be significantly dependent on Golden Sunrise's management team. Golden Sunrise's success will be particularly dependent upon Mr. Loeffler, President, Mr. Tieu, Chief Science Officer, and Mrs. Fontana, Chief Medical Officer of Golden Sunrise, and developer of Golden Sunrise operations, and manager of the business. The loss of these individuals could have a material adverse effect on Golden Sunrise.

Risks Associated with Expansion

Golden Sunrise plans on expanding its business through the introduction of a sophisticated marketing campaign. Any expansion of operations Golden Sunrise may undertake will entail risks; such legal actions may involve specific operational activities which may negatively impact the profitability of Golden Sunrise. Consequently, NutraCoin tokens must assume the risk that (i) such expansion may ultimately involve expenditures of funds beyond the resources available to Golden Sunrise at that time, and (ii) management of such expanded operations may divert management's attention and resources away from its existing operations, all of which factors may have a material adverse effect on Golden Sunrise's present and prospective business activities.

Customer Base and Market Acceptance

While Golden Sunrise believes it can further its customer base, and develop new customers through its marketing, promotion and distribution of its product line, the inability of Golden Sunrise to further such a customer base could have material adverse effects on Golden Sunrise. Although Golden Sunrise believes that its product line would give advantages over competitor company's products, no assurance can be given that Golden Sunrise dietary supplement products will attain any degree of market acceptance on a sustained basis or that it will generate revenues sufficient for sustained profitable operations.

Competition

Golden Sunrise has a unique product line that can cross the lines of both the pharmaceutical and dietary supplement sectors. Each of these sectors has its own drawbacks. First, the dietary supplements sector has nutritional products that provide an alternate nutrition source that have no side-effects to human health. These products cannot treat patients with *Serious or Life-threatening* diseases or conditions, including *Cancer* except to only provide nutritional supplementation in a person's diet. Secondly, pharmaceutical medications provide treatment for patients but have harmful side-effects that are sometimes more adverse to the patient than the disease that is being treated.

While there does exist some competition from both these sectors, Golden Sunrise management believes that its product line is unique in nature and the expertise of management combined with the New Medical Innovative nature of its products will set Golden Sunrise dietary supplement products apart from its competitors. There is the possibility that new competitors could seize upon Golden Sunrise product ideas and produce similar competitive product lines. These new competitors could be better capitalized than Golden Sunrise which could give them a significant advantage. This would give the possibility that competitors could capture a significant market share of Golden Sunrise's intended market.

General Economic Conditions

The financial success of Golden Sunrise may be sensitive to adverse changes in general economic conditions in the U.S., such as recession, inflation, unemployment, and interest rates. Such changing conditions could reduce demand in the marketplace for Golden Sunrise's products. Management believes that the niche products they market, and the extensive product line of Golden Sunrise will insulate Golden Sunrise from excessively reduced demand. Nevertheless, Golden Sunrise has no control over these changes.

Trend in Consumer Preferences and Spending; Possible Fluctuations in Operating Results

Golden Sunrise's operating results may fluctuate significantly from period to period as a result of a variety of factors, including purchasing patterns of customers, competitive pricing, debt service and principal reduction payments, and general economic conditions. There is no assurance that Golden Sunrise will be successful in marketing any of its products, or that the revenues from the sale of such products will be significant. Consequently, Golden Sunrise's revenues may vary by quarter, and Golden Sunrise's operating results may experience fluctuations.

Risks of Borrowing

If Golden Sunrise incurs indebtedness, a portion of its cash flow will have to be dedicated to the payment of principal and interest on such indebtedness. Typical loan agreements also might contain restrictive covenants which may impair Golden Sunrise's operating flexibility. Such loan agreements would also provide for default under certain circumstances, such as failure to meet certain financial covenants. A default under a loan agreement could result in the loan becoming immediately due and payable and, if unpaid, a judgment in favor of such lender which would supersede the rights of NutraCoin token of Golden Sunrise. A judgment creditor would have the right to foreclose on any of Golden Sunrise's assets resulting in a material adverse effect on Golden Sunrise's business, operating results or financial condition.

Unanticipated Obstacles to Execution of the NutraCoin White Paper

NutraCoin white paper may change significantly. Many of Golden Sunrise's potential business endeavors are capital intensive and may be subject to statutory or regulatory requirements. Management believes that Golden Sunrise's chosen activities and strategies are achievable in light of current economic and legal conditions with the skills, background, and knowledge of Golden Sunrise's principals and advisors. Management reserves the right to make significant modifications to Golden Sunrise's stated strategies depending on future events.

Management Discretion to Use Proceeds

The net proceeds from this Offering will be used for the purposes described under "Use of Proceeds." Golden Sunrise reserves the right to use the funds obtained from this Offering for other similar purposes not presently contemplated which it deems to be in the best interest of Golden Sunrise and its NutraCoin tokens in order to address changed circumstances or opportunities. As a result of the foregoing, the success of Golden Sunrise will be substantially dependent upon the discretion and judgment of Management with respect to application and allocation of the net proceeds of this Offering. Investors for the NutraCoin Token offered hereby will be entrusting their funds to Golden Sunrise's Management, upon whose judgment, and discretion the investors must depend.

No Assurances of Protection for Proprietary rights; Reliance on Trade Secrets

In certain cases, Golden Sunrise may rely on trade secrets to protect proprietary technology and processes which Golden Sunrise has developed or may develop in the future. There can be no assurance that secrecy obligations will be honored or that others will not independently develop similar or superior technology. The protection of proprietary technology through claims of trade secret status has been the subject of increasing claims and litigation by various companies both in order to protect proprietary rights as well as for competitive reasons even where proprietary claims are unsubstantiated. The prosecution of proprietary claims or the defense of such claims is costly and uncertain given the uncertainty and rapid development of the principles of law pertaining to this area. Golden Sunrise, in common with other firms, may also be subject to claims by other parties with regard to the use of technological information and data which may be deemed proprietary to others.

Compliance with Securities Laws

The NutraCoin Tokens are being offered for sale in reliance upon certain exemptions from the registration requirements of the Securities Act, applicable Delaware Securities Laws, and other applicable state securities laws. If the sale of Tokens were to fail to qualify for these exemptions, purchasers may seek rescission of their purchases of Tokens. If a number of purchasers were to obtain rescission, Golden Sunrise would face significant financial demands which could adversely affect Golden Sunrise as a whole, as well as non-rescinding purchasers.

Offering Price

The price of the NutraCoin Tokens offered has been arbitrarily established by Golden Sunrise, considering such matters as the state of Golden Sunrise's business development and the general condition of the industry in which it operates. The Offering price bears little relationship to the assets, net worth, or any other objective criteria of value applicable to Golden Sunrise.

Projections: Forward Looking Information

Management has prepared projections regarding Golden Sunrise's anticipated financial performance. Golden Sunrise's projections are hypothetical and based upon the historical financial performance of Golden Sunrise, the addition of a sophisticated and well-funded marketing plan, and other factors influencing the business of Golden Sunrise. The projections are based on Management's best estimate of the probable results of operations of Golden Sunrise, based on present circumstances, and have not been reviewed by Golden Sunrise's independent accountants. These projections are based on several assumptions, set forth therein, which Management believes are reasonable. Some assumptions upon which the projections are based, however, invariably will not materialize due to the inevitable occurrence of unanticipated events and circumstances beyond Management's control. Therefore, actual results of operations will vary from the projections, and such variances may be material. Assumptions regarding future changes in sales and revenues are necessarily speculative in nature. In addition, projections do not and cannot take into account such factors as general economic conditions, unforeseen regulatory changes, the entry into Golden Sunrise's market of additional competitors, the terms and conditions of future capitalization, and other risks inherent to Golden Sunrise's business. While Management believes that the projections accurately reflect possible future results of Golden Sunrise's operations, those results cannot be guaranteed.

XV. PROJECT FUNDING

Fund Use of Proceeds

The proceeds raised from Accredited Investors by NutraCoin token funding will be applied for the following use for Golden Sunrise: To populate Golden Sunrise's administration and staff as needed for the function of Golden Sunrise activities, build Golden Sunrise infrastructure, apply funds for manufacturing including third (3rd) party manufacturing and possible acquiring of facilities for in house manufacturing, build a M&A department to acquire properties needed in the administration, manufacturing, IT developers, promotions and marketing, healthcare facilities, or other outlets for product sales, nutraceutical and pharmaceutical licensing, to cover any litigation that may occur, and accumulate working capital for other uses.

Golden Sunrise will establish an IHA with Wells Fargo bank or Chase bank in California, into which the offering proceeds will be placed. At least twenty thousand (\$20,000.00) dollars before such proceeds will be released from the escrow account and utilized by Golden Sunrise. After the number of NutraCoin tokens are sold, all subsequent proceeds from the sale of NutraCoin tokens will be delivered directly to Golden Sunrise.

Golden Sunrise will benefit from clinic, other medical and health facilities acquisitions and building new clinics for market expansion:

- **Oakview Medical Group:** Established clinic in VISALIA California 93291.

Blockchain App development is the process of creating decentralized applications that use blockchain technology to ensure security, transparency, and immutability. The development lifecycle involves defining the problem and use case, selecting the right blockchain platform and consensus mechanism, designing the architecture and UI and UE, developing smart contract blockchain, white label crypto exchange, rigorous testing, and ongoing maintenance. Benefits include enhanced security, cost savings, improved efficiency, and greater data integrity through the elimination of intermediaries:

- **Apptunix Technologies Pvt, Ltd.:** Website www.apptunix.com and Apptunix Proposal developing NutraCoin App.

Contract manufactures are specialized third-party companies that produce health supplement products (like vitamins, minerals, dietary supplements), handling everything from formulation and sourcing to manufacturing, quality control, and packaging, allowing the brand to focus on marketing and sales without investing in costly facilities and staff. They offer expertise, efficiency, and cost savings, ensuring products meet quality standards and regulations like GMP.

- **WePackItAll:** Website www.wepackitall.com.
 - **PureNSM:** Nutritional Supplement Manufactures, Inc. in CHULA VISTA California. Website www.purensn.com.

XVI. LICENSING

Golden Sunrise Pharmaceutical, Inc. shall out-license to Golden Sunrise Nutraceutical, Inc. This AGREEMENT dated as of July 01, 2017 is made between Golden Sunrise Nutraceutical, Inc., a Delaware corporation, having its principal place of business at PORTERVILLE California and Golden Sunrise Pharmaceutical, Inc., a California corporation, having its principal place business at PORTERVILLE California. Golden Sunrise Pharmaceutical has developed and obtained patent, trademark rights to certain Cosmetic, dietary supplement, Drug, and FDA applications. Golden Sunrise Nutraceutical desires to license from Golden Sunrise Pharmaceutical the right to develop, market, make, use, and sell certain cosmetic, dietary supplement, and drug formulations which are applied to humans and animals through the use of the New Medical Innovation. In consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged Golden Sunrise Nutraceutical and Golden Sunrise Pharmaceutical agree as follows:

- **Definitions:** As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:

“NEW MEDICAL INNOVATION” means any New Medical Innovation owned or licensable by Golden Sunrise Pharmaceutical, Inc. which relates to dietary supplement, drug, and compositions for the topical application of ointment.

“GOLDEN SUNRISE PHARMACEUTICAL PATENT, TRADEMARK, AND TRADE SECRET RIGHTS” means all patents, trademarks, trade secret, FDA applications (which for all purposes of this Agreement shall be deemed to include certificates of invention, applications for certificates of invention, and utility models) throughout the world, covering or relating to the Technology including any substitutions, extensions, reissues, reexaminations, renewals, divisions, continuations, or continuations-in-part, which Golden Sunrise Pharmaceutical owns or controls, and under which Golden Sunrise Pharmaceutical has the right to grant sub-licenses to Golden Sunrise Nutraceutical as of July 01, 2017 Agreement and thereafter including, but not limited to U.S.. All current patent, trademark, trade secret, and FDA applications in the Golden Sunrise Pharmaceutical Patent and Trademark rights are listed in U.S. Patent and Trademark Office.

“GOLDEN SUNRISE PHARMACEUTICAL TECHNOLOGY RIGHTS” means all technical information owned or possessed by Golden Sunrise Pharmaceutical as of July 01, 2017 Agreement and thereafter, whether patentable and/or otherwise, relating to Technology which information is necessary or useful for Golden Sunrise Nutraceutical and its sub-licensees to develop, manufacture, use, and/or sell Licensed Products hereunder.

“CONFIDENTIAL INFORMATION” means all materials, trade secrets, or other information, including, without limitation, proprietary information and materials (whether or not patentable) regarding a Party’s technology, products, business information, or objectives, which is designated as confidential in writing by the disclosing Party, whether by letter or by the use of an appropriate stamp or legend, prior to or at the time any such material, trade secret, or other information is disclosed by the disclosing Party to the other Party. Notwithstanding the foregoing to the contrary, materials, trade secrets, or other information which is orally or visually disclosed by a Party, or is disclosed in writing without an appropriate letter, stamp, or legend, shall constitute Confidential Information if the disclosing Party, within thirty (30) days after such disclosure, delivers to the other Party a written document or documents describing the materials, trade secrets, or other information and referring the place and date of such oral, visual or written disclosure and the names of the persons to whom such disclosure was made.

“FIELD” means the human topical delivery ointment formulations, including but not limited to human topical delivery to the skin, intranasal cavities, and but excluding oral cavity.

“LICENSED PRODUCTS” means a product which, or the manufacture, use, or sale of which, is covered by a Valid Claim of any of the Golden Sunrise Pharmaceutical Patent and Trademark Rights where the product is manufactured, used or sold and/or embodies any Golden Sunrise Pharmaceutical Technology Rights.

“NET SALES” shall mean the gross amount actually received by Golden Sunrise Nutraceutical on sales of Licensed Products, less: (a) credits or allowances, if any, actually granted; (b) discounts actually allowed; (c) freight, postage, and insurance charges and additional special packaging charges and; (d) customs duties, and excises, sales, taxes, duties or other taxes imposed upon and paid with respect to such sales (excluding what is

commonly known as income taxes). In the case of any Licensed Products supplied to Golden Sunrise Nutraceutical by Golden Sunrise Pharmaceutical. "Net Sales" shall mean the amount as defined in the proceeding sentence, less the amount paid by Golden Sunrise Nutraceutical to Golden Sunrise Pharmaceutical for Golden Sunrise Pharmaceutical to supply the Licensed Products.

"PARTY" means Golden Sunrise Nutraceutical or Golden Sunrise Pharmaceutical; "Parties" mean Golden Sunrise Nutraceutical and Golden Sunrise Pharmaceutical.

"VALID CLAIM" means a claim of any unexpired U.S. or foreign patent and trademark or patent and trademark application which shall not have been withdrawn, canceled, or disclaimed, nor held invalid by a Court of Competent Jurisdiction in an or unappeasable decision.

LICENSE. Subject to the payment of the royalties provided under section "LICENSE FEES AND ROYALTIES" and the fulfillment of the other terms and conditions of this Agreement. Golden Sunrise Pharmaceutical hereby grants to Golden Sunrise Nutraceutical a worldwide, exclusive license under all of Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights Golden Sunrise Pharmaceutical Technology Rights, including the right to sublicense any or all of such rights, to make, have made, use, have used, sell, and have sold Technology in the Field.

ASSISTANCE. Golden Sunrise Pharmaceutical shall provide Golden Sunrise Nutraceutical with all information related to the Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights and Golden Sunrise Pharmaceutical Technology Rights as any be known or possessed by Golden Sunrise Pharmaceutical and as may reasonably necessary for Golden Sunrise Nutraceutical to exploit the licenses granted under section "LICENSE", including any materials related to the acquisition of any government approvals for the Licensed Products. Golden Sunrise Pharmaceutical shall assist Golden Sunrise Nutraceutical with reasonable technical assistance in connection with such transfer of the information related to the Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights and Golden Sunrise Pharmaceutical Technology Rights.

LICENSE FEES AND ROYALTIES. (a) Golden Sunrise Nutraceutical shall pay to Golden Sunrise Pharmaceutical, during the applicable term described in "LICENSE FEES AND ROYALTIES" below, a royalty of five (5%) percent on all Net Sales by Golden Sunrise Nutraceutical of Licensed Products covered by a Valid Claim of a patent, trademark, and trade secret application of the Golden Sunrise Pharmaceutical Patent and Trademark Rights. (b) The obligation of Golden Sunrise Nutraceutical to pay royalties on sales of Licensed Products covered by a Valid Claim of a patent, trademark, and trade secret of the Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights shall terminate on a country-by-country basis concurrently with the expiration or termination of the applicable Valid Claim under the Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights in the country in which the product is manufactured, used, or sold. (c) In no event shall more than one (1) royalty be due Golden Sunrise for any Licensed Product sold by Golden Sunrise Nutraceutical. (d) Upon the expiration of the royalty obligations of section "LICENSE FEES AND ROYALTIES (a)" in accordance with section "LICENSE FEES AND ROYALTIES (b)" for all or any portion of the Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights, the licenses granted pursuant to section "LICENSE"

shall become, with respect to such Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights and the Golden Sunrise Pharmaceutical Technology Rights, or portion thereof, fully paid.

SUB-LICENSE FEES. Golden Sunrise Nutraceutical shall pay Golden Sunrise Pharmaceutical on account of sub-licenses under the Golden Sunrise Pharmaceutical Patent, Trademark, and Trade Secret Rights and Golden Sunrise Pharmaceutical Technology Rights less all appropriate expenses (including attorneys' fees) associated with such sub-licenses unsecured by Golden Sunrise Nutraceutical. However, if Golden Sunrise Pharmaceutical supplies Licensed Products to sub-licensees of Golden Sunrise Nutraceutical pursuant to sub-licenses, Golden Sunrise Pharmaceutical shall supply such Licensed Products at its cost.

XVII. CONCLUSION

Golden Sunrise dietary supplement products revolutionize healthcare and wellness for treatment of patients and NutraCoin is providing security and growth. NutraCoin merges nutraceuticals with cutting-edge blockchain in a five trillion (\$5,000,000,000.000.00) dollar market. With transparent tokenomics, ironclad Security, and a fundraising roadmap, join Golden Sunrise Nutraceutical to define Health, Wealth, and Helping Mankind. Visit www.goldensunrisenutraceutical.com.

Eqvista Final Report on May 20, 2025 (**Exhibit "A"**).

XVIII. FREQUENTLY ASKED QUESTIONS

What is NutraCoin?

A Security NutraCoin token powering Golden Sunrise Nutraceutical's ecosystem on the Blockchain.

Is NutraCoin Secure?

Yes! Audited by the SEC, FDA Inspection, Audited contracts, and multi-signature wallets.

Why Aging and Longevity is a Huge Value?

- **Disease Prevention:** Targeting aging and longevity to slow down chronic diseases, Serious or Life-threatening conditions, and cancer it's at their roots, preventing massive healthcare costs.
- **Healthspan Extension:** It's not just about living longer, but living *healthier* longer, and improving the *quality-of-life* for productivity.
- **Societal Shift:** With more people living longer, there's a massive demand for solutions that support extended healthy living, creating a huge market.

References

[1] Grand View Research (2024). Nutraceuticals Market Size Report

<https://www.grandviewresearch.com/industry-analysis/nutraceuticals-market>

[2] Nielsen (2024). Consumer Trust in Health Products Survey

<https://www.nielsen.com/insights/2024/maximizing-roi-in-a-fragmented-world-nielsen-annual-marketing-report/>

- [3] MarketWatch (2025). Global Nutraceutical Market Forecast. Under “AI Overview”
https://www.google.com/search?q=MarketWatch+%282025%29+Global+Nutraceutical+Market+Forecast&client=firefox-b-1-d&sca_esv=d3099a39e25ef03c&channel=entpr&ei=B-zraLLvO9Ouur8P75rZgQ8&ved=0ahUKEwjyrOSnp-QAxVTI-4BHW9NNvAQ4dUDCBA&uact=5&oq=MarketWatch+%282025%29+Global+Nutraceutical+Market+Forecast&gs_lp=Exgnd3Mtd2l6LXNlcnAiN01hcmtldFdhdGNoICgyMDI1KSBHbG9iYWwgTnV0cmFjZXV0aWNhbCBNYXJrZXQgRm9yZWNhczQyBRAhGKABMgUQIRigATIFECEYoAEyBRAhGKABMgUQIRirAjIFECEYqwIyBRAhGKsCSPBNUJ8MWIMScAF4AJABAJgBngGgAeQDqgEDMS4zuAEDyAEA-AEBmAlFoAKJBclCDhAAGIAEGIoFGIYDGLADwgILEAAyGaoYogOYsAPCAgsQABiJB RiiBBiwA8ICCBAAAG08FGLADwgILEAAyIQUYogTCAgUQABjvBcICCBAAAGIAEGKIEwglIECEYoAEYwwSYAwCIBgGQBgeSBwMxLjSgB5IQsgcDMC40uAfKBMiHBzItMS4zLjHIB1Y&scient=gws-wiz-serp
- [4] Tieu, H. and Loeffler, M. (2022) Life Is Quantum Biology Effects Explained from the Schrödinger Equation, Serious or Life-Threatening Conditions or Diseases, and COVID-19 Results. Journal of Biosciences and Medicines, DOI No.: 10.4236/jbm.2022.1010013
<https://doi.org/10.4236/jbm.2022.1010013>
- [5] Tieu, H. and Loeffler, M. (2023) Tieu Equation Experimentation of Understanding by Energy Transfer Quantum Mechanics. Natural Science, DOI No.: 10.4236/ns.2023.153008
<https://www.scirp.org/journal/paperinformation?paperid=123783>
- [6] Tieu, H., Loeffler, M., and Ayala, E. (2023) Huu S. TIEU Request for FDA to Establish Regenerating Human Cells as Law on December 13, 2016 President Barack H. Obama Signed the 21st Century CURES Act into FDA Regulation and Law. Open Journal of Regenerative Medicine, DOI No.: 10.4236/ojrm.2022.113004
<https://www.scirp.org/journal/paperinformation?paperid=122400>
- [7] Tieu, H. and Loeffler, M. (2023) Particle Becomes Energy = Energy Becomes Mass, DOI No.: 10.17406/GJSFR, Volume 23 Issue 4 Version 1.0
[https://globaljournals.org/GJSFR_Volume23/E-Journal_GJSFR_\(A\)_Vol_23_Issue_4.pdf](https://globaljournals.org/GJSFR_Volume23/E-Journal_GJSFR_(A)_Vol_23_Issue_4.pdf)
- [8] Tieu, H. and Loeffler, M. (2023) Huu S. TIEU’s Predicting Outcome of Severe Acute Respiratory Syndrome (SARS) and Preparing the Treatment for COVID-19 (Coronavirus) and Other Viral Pandemics. International Journal of Clinical Medicine, DOI No.: 10.4236/ijcm.2023.142008
<https://www.scirp.org/journal/paperinformation?paperid=123247>
- [9] Physics and Space Science (2023), Particle Becomes Energy = Energy Becomes Mass by Huu S. Tieu & Martin F. Loeffler, DOI No.: 10.17406/GJSFR, Volume 23 Issue 4 (Version 1.0)
[https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://globaljournal.s.org/GJSFR_Volume23/E-Journal_GJSFR_\(A\)_Vol_23_Issue_4.pdf&ved=2ahUKEwiaodfMn5-QAxWIBbwBHQWQftoQFnoECEUQAQ&usg=AOvVaw0hfeD_1UgL7EyYDwrjPr3S](https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://globaljournal.s.org/GJSFR_Volume23/E-Journal_GJSFR_(A)_Vol_23_Issue_4.pdf&ved=2ahUKEwiaodfMn5-QAxWIBbwBHQWQftoQFnoECEUQAQ&usg=AOvVaw0hfeD_1UgL7EyYDwrjPr3S)
- [10] Food and beverage innovation plunges nearly 50% since 2007: Mintel
<https://www.fooddive.com/news/food-and-beverage-innovation-plunges-mintel/721918/>
- [11] The 46,000% Biotech Rocket: How No-Revenue Stock Hit \$30 Billion
<https://finance.yahoo.com/news/46-000-biotech-rocket-no-164308440.html>
- [12] What We Know About a Hong Kong TCM Stock That Spiked 82,000%
<https://www.bloomberg.com/news/newsletters/2025-06-26/what-we-know-about-hong-kong-tcm-firm-regencell-s-82-000-stock-spike>
- [13] Nasdaq-trade Chinese herb stock with no revenues rallies 59,000% to top Lululemon in market value
<https://www.cnbc.com/2025/06/17/hong-kongs-regencell-bioscience-triples-in-latest-surge-for-a-speculative-stock.html>

[14] NIH – International Gains to Achieving Healthy Longevity

<https://pmc.ncbi.nlm.nih.gov/articles/PMC9899644/>

[15] This Is the \$8 Trillion Investment Opportunity VCs and Founders Can't Ignore

<https://www.entrepreneur.com/leadership/this-is-the-8-trillion-opportunity-vcs-and-founders-cant/502671>

Golden Sunrise Nutraceutical, Inc.

P.O. Box 510
PORTERVILLE, CA 93258

SUBSCRIPTION AGREEMENT

Ladies and Gentlemen:

You have informed the undersigned for Purchaser (the “Purchaser”) that Golden Sunrise Nutraceutical, Inc. (the “Company”), a Delaware corporation, wishes to raise fund selling NutraCoin (GSN) Token (the “Tokens”), at a price of one (\$1.00) dollar per Token.

I received, read, and understand the Confidential Limited Offering White Paper (the “White Paper”) January 01, 2026. I further understand that my rights and responsibilities as a Purchaser will be governed by the terms and conditions of this Subscription Agreement, the White Paper. I understand that you will rely on the following information to confirm that I am an “Accredited Investor”, as defined in Regulation D promulgated under the Securities Act of Year-1933, as amended (the “Securities Act”), will be allowed to purchase Tokens in this Offering (subject to Company approval), and that I am qualified to be a Purchaser.

This Subscription Agreement is one (1) of a number of such subscriptions for Tokens. By signing this Subscription Agreement, I offer to purchase and subscribe from the Company the number of Tokens set forth below of the terms specified herein. The Company reserves the right, in its complete discretion, to reject any subscription offer or to reduce the number of Tokens allotted to me, if I am not able to meet the dollar amount required. If this offer is accepted, the Company will execute a copy of this Subscription Agreement and return it to me. I understand that commencing on the date of this White Paper all funds received by the Company in full payment of subscriptions for Tokens will be deposited in an escrow account. The Company has established an Investment Holding Account with Wells Fargo Bank in Porterville, California, into which the minimum offering proceeds will be placed.

1. Accredited Investor. I am an Accredited Investor because I qualify within one (1) of the following categories:

Please Check The Appropriate Category

___ One Million (\$1,000,000.00) Dollars Net Worth.

A natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds one million (\$1,000,000.00) dollars.

___ Two Hundred/Three Hundred Thousand (\$200,000.00/\$300,000.00) Dollars Income.

Purchaser’s Initials

A natural person who has an individual income in excess of two hundred thousand (\$200,000.00) dollars (including contributions to qualified employee benefit plans) or joint income with such person's spouse in excess of three hundred thousand (\$300,000.00) dollars per year in each of the two (2) most recent years and who reasonably expects to attain the same individual or joint levels of income (including such contributions) in the current year.

___ Director or Officer of Issuer.

Any director or executive officer of the Company.

___ All Equity Owner In Entity Are Accredited Investor.

An entity, (i.e. corporation, partnership, trust, Individual Retirement Account (IRA), etc.) in which all of the equity owners are Accredited Investors as defined herein.

___ Corporation.

A corporation not formed for the specific purpose of acquiring the Tokens offered, with total assets in excess of five million (\$5,000,000.00) dollars.

Representations and Warranties. I represent and warrant to the Company that:

- (a) I (i) have adequate means of providing for my current needs and possible contingencies and I have no need for liquidity of my investment in the Tokens, (ii) can bear the economic risk of losing the entire amount of my Investment in Tokens, and (iii) have such knowledge and experience that I am capable of evaluating the relative risks and merits of this investment; (iv) the purchase of Tokens is consistent, in both nature and amount, with my overall investment program and financial condition.
- (b) The address set forth below is my true and correct residence, and I have no intention of becoming a resident of any other state or jurisdiction.
- (c) I have not utilized the services of a "Purchaser Representative" (as defined in Regulation D promulgated under the Securities Act) because I am a sophisticated, experienced investor, capable of determining and understanding the risks and merits of this investment.
- (d) I have received and read, and am familiar with the Token Documents, including the White Paper and the forms of certificate for Tokens. All documents, records and books pertaining to the Company and the Tokens requested by me, including all pertinent records of the Company, financial and otherwise, have been made available or delivered to me.

Purchaser's Initials

- (e) I have had the opportunity to ask questions of and receive answers from the Company's officers and representatives concerning the Company's affairs generally and the terms and conditions of my proposed investment in the Tokens.
- (f) I understand the risks implicit in the business of the Company. Among other things, I understand that there can be no assurance that the Company will be successful in obtaining the funds necessary for its success. If only a fraction of the maximum amount of the Offering is raised, the Company may not be able to expand as rapidly as anticipated, and proceeds from this Offering may not be sufficient for the Company's long term needs.
- (g) Other than as set forth in the White Paper, no person or entity has made any representation or warranty whatsoever with respect to any matter or thing concerning the Company and this Offering, and I am purchasing the Tokens based solely upon my own investigation and evaluation.
- (h) I understand that no Tokens have been registered under the Securities Act, nor have they been registered pursuant to the provisions of the Securities or other laws of applicable jurisdictions.
- (i) The Tokens for which I subscribe are being acquired solely for my own account, for investment and are not being purchased with view to or for their resale or distribution. In order to induce the Company to sell Tokens to me, the Company will have no obligation to recognize the ownership, beneficial or otherwise, of the Tokens by anyone but me.
- (j) I am aware of the following:
 - (1) The Shares are a speculative investment which involves a high degree of risk; and
 - (2) My investment in the Tokens is not readily transferable; it may not be possible for me to liquidate my investment.
 - (3) Year-2025 will be the first full year of the Company. The financial statements of the Company for the year ending December 31, 2025 will be reviewed or audited.
 - (4) There are substantial restrictions on the transferability of the Tokens registered under the Securities Act; and
 - (5) No Federal or State agency has made any finding or determination as to the fairness of the Tokens for public investment nor any recommendation or endorsement of the Tokens;

Purchaser's Initials

- (k) Except as set forth in the White Paper, none of the following information has ever been represented, guaranteed, or warranted to me expressly or by implication, by any broker, the Company, or agents or employees of the foregoing, or by any other person:
- (1) The appropriate or exact length of time that I will be required to hold the Tokens;
 - (2) The percentage of profit and/or amount or type of consideration, profit, or loss to be realized, if any, as a result of an investment in the Tokens; or
 - (3) That the past performance or experience of the Company, or associates, agents, affiliates, or employees of the Company or any other person, will in any way indicate or predict economic results in connection with the purchase of Tokens;
 - (4) The amount of dividends or distribution that the Company will make;
- (l) I have not distributed the White Paper to anyone, no other person has used the White Paper, and I have made no copies of the White Paper; and
- (m) I hereby agree to indemnify and hold harmless the Company, its officers, directors, and representatives from and against any all liability, damage, cost or expense, including reasonable attorney's fees, incurred on account of or arising out of:
- (1) Any inaccuracy in the declarations, representations, and warranties set forth above;
 - (2) The disposition of any of the Tokens by me which is contrary to the foregoing declarations, representations, and warranties; and
 - (3) Any action, suit or proceeding based upon (i) the claim that said declarations, representations, or warranties were inaccurate or misleading or otherwise cause for obtaining damages or redress from the Company; or (ii) the disposition of any of the Tokens.
- (n) By entering into this Subscription Agreement, I acknowledge that the Company is relying on the truth and accuracy of my representations.

The foregoing representation and warranties are true and accurate as of the date hereof, shall be true and accurate as of the date of the delivery of the funds to the Company and shall survive such delivery. If, in any respect, such representations and warranties are not true and accurate prior to delivery of the funds, I will give written notice of the fact to the Company, specifying which representations and warranties are not true and accurate and the reasons therefor.

Purchase's Initials

2. Transferability. I understand that I may sell or otherwise transfer my Tokens only if registered under the Securities Act or I provide the Company with an opinion of counsel acceptable to the Company to the effect that such sale or other transfer may be made in absence of registration under the Securities Act. I have no right to cause the Company to register the Tokens. Any certificates or other documents representing my Tokens will contain a restrictive legend reflecting this restriction, and stop transfer instructions will apply to my Tokens.
3. Indemnification. I understand the meaning and legal consequences of the representations and warranties contained in Paragraph two (2) hereof, and I will indemnify and hold harmless the Company, its officers, directors, and representatives involved in the offer or sale of the Tokens to me, as well as each of the managers and representatives, employees and agents and other controlling persons of each of them, from and against any and all loss, damage or liability due to or arising out of a breach of any representation or warranty of mine contained in this Subscription Agreement.
4. Revocation. I will not cancel, terminate or revoke this Subscription Agreement or any agreement made by me hereunder and this Subscription Agreement shall survive my death or disability.
5. Termination of Agreement. If this subscription is rejected by the Company, then this Subscription Agreement shall be null and void and of no further force and effect, no party shall have any rights against any other party hereunder, and the Company shall promptly return to me the funds delivered with this Subscription Agreement.
6. Miscellaneous.
 - (a) This Subscription Agreement shall be governed by and construed in accordance with the substantive law of the State of Delaware.
 - (b) This Subscription Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and may be amended only in writing and executed by all parties.

Purchaser's Initials

7. Ownership Information. Please print here the total number of Tokens to be purchased, and the exact name(s) in which the Tokens will be registered.

Total Tokens: _____

Name(s): _____

- _____ Single Person
_____ Husband and Wife, as community property
_____ Joint Tenants (with right of survivorship)
_____ Tenants in Common
_____ A Married Person as separate property
_____ Corporation or other organization
_____ A Partnership
_____ Trust
_____ IRA
_____ Tax-Qualified Retirement Plan
(i) Trustee(s)/Custodian _____
(ii) Trust Date _____
(iii) Name of Trust _____
(iv) For the Benefit of _____

_____ Other: _____
(Please explain)

Social Security or Tax I.D. Number: _____

Residence Address:

_____ Street Address

_____ City State Zip

Mailing Address: (Complete only if different from residence)

_____ Street Address (If P.O. Box, include address for surface delivery if different than residence)

_____ City State Zip

Purchaser's Initials

Phone Numbers

Home No.: (_____) _____

Business No.: (_____) _____

Facsimile No.: (_____) _____

8. Date and Signatures.

Dated _____.

Signature

Purchaser Name (Print)

(Each co-owner or joint owner must sign – Name must be signed exactly as listed under
“Purchaser Name”)

ACCEPTED:

GOLDEN SUNRISE NUTRACEUTICAL, INC.

By: _____

Dated: _____, 2026

Martin F. LOEFFLER
President/CEO

Purchaser’s Initials